ESMO 2020: COMBI-i Fails to Demonstrate Benefit of Adding Spartalizumab to Dabrafenib and Trametinib For Unresectable/Metastatic Melanoma
Subanalyses suggest potential benefits in certain patient subsets
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.